Compare GCTK & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCTK | CDT |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.4M |
| IPO Year | 2011 | N/A |
| Metric | GCTK | CDT |
|---|---|---|
| Price | $0.33 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 404.1K | ★ 12.2M |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $589,462.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.29 | $0.37 |
| 52 Week High | $14.14 | $11.00 |
| Indicator | GCTK | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 31.05 | 35.84 |
| Support Level | $0.29 | N/A |
| Resistance Level | $0.73 | $0.73 |
| Average True Range (ATR) | 0.03 | 0.23 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 9.47 | 1.87 |
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.